



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
OGATA et al.)	Group Art Unit: 1646
Application No.: 10/019,571)	Examiner: Ruixiang Li
§ 371 Date: December 31, 2001			
PCT Filing Date: July 3, 2000			
For:	THERAPEUTIC AGENT FOR DISEASES CAUSED BY PTH OR PTHrP)	
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313			
Sir:			

Statement Under 37 C.F.R. §§ 1.821 and 1.825

In accordance with 37 C.F.R. §§ 1.821(f) and 1.825(b), Applicants assert that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written Substitute Sequence Listing submitted herewith.

Applicants further assert under §§ 1.821(g) and 1.825(a) that the Substitute Sequence Listing submitted herewith contains no new matter. Applicants also submit a Declaration pursuant to In Re Hawkins herewith, which asserts that the sequence of the PTH/PTHrP receptor (SEQ ID NO. 76) consists of the same material incorporated by

PATENT Customer No. 22,852 Attorney Docket No. 04853.0086 Application No. 10/019,571

reference in the above-identified application, and thus no new matter has been added.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: November 18, 2004

ŧ,

Зу: ____

Amy E. Purcell

Reg. No. 53,492